Oncology Central

Cancer vaccines for hepatocellular carcinoma: future directions

0

Hepatocellular carcinoma (HCC) is the third and the fifth leading cause of death from cancer globally in men and women, respectively. The overall prognosis for HCC patients is poor, with a dismal 5-year survival rate of approximately 5–6%. The majority of patients are diagnosed when disease can be treated only with locoregional therapies resulting in limited survival benefits and tumor recurrence in 50–80% of patients at 5 years after treatment [1].

To view restricted content, please:
Share:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.